About
Brand story
In 2019, during developing novel anti-cancer
therapies, Dr. Chen’s lab, a team of Chinese-
American biologists in the U.S., serendipitously
discovered the breakthrough process for
standardized production of recombinant
exosomes.
In 2019, during developing novel anti-cancer
therapies, Dr. Chen’s lab, a team of Chinese-
American biologists in the U.S., serendipitously
discovered the breakthrough process for
standardized production of recombinant
exosomes.
This led to the founding of AESOMED, shifting
focus to anti-aging science. After over a thousand
formulations, the optimal balance between active
ingredients and skin cells was achieved on the
313th trial. Combining patented recombinant
exosomes with our 313rd formulation, we created
signature anti-aging produc—FORMULA 313.
More than a breakthrough in science, this
laboratory-derived serial number, unveils a new
chapter in regenerative aesthetics.
More than a breakthrough in science, this
laboratory-derived serial number, unveils a new
chapter in regenerative aesthetics.
THE NEXT CHAPTER OF
REGENERATION.
Team
Ming LI
CEO，Co-Founder
- Over 12 years of experience in healthcare investment and management
- Founder of the healthcare investment firm, Kuanping Capital
- Former core member of the healthcare teams at Hillhouse Capital and FountainVest Partners
- Dual Bachelor’s degrees in Mathematics and Economics, Peking University
Dr. Yiyou CHEN
Science Co-Founder
- Serial biotech entrepreneur
- Successfully founded companies including New Horizon Health, CrownBio, and ImmuneOnco
- B.S. in Biochemistry, Peking University;Ph.D. in Experimental Pathology, University of Utah
Sherry SHAO
COO ， Co-Founder
- Over 10 years of investment experience in consumer and technology sectors
- Former Investment Director at FountainVest Partners, CMC Capital, and Alibaba Strategic Investments
- B.A. in Economics, Renmin University; M.S. in Business, University of Illinois at Urbana-Champaign
Dr. Zhixiang WU
R&D Director
- Extensive experience in biotechR&D and clinical research
- Ph.D. in Biology, Shanghai Jiao Tong University
Company
Strive to become
A leading global brand in regenerative medicine
Shanghai
China Headquarter and R&D Center
Biopharmaceutical-grade
P1-level biosafety lab
Beijing
Biopharmaceutical-grade GMP
Recombinant exosome production and purification
Specialized intelligent manufacturing
Seattle
North America Headquarter
FDA-compliant recombinant exosome manufacturing facility
Hongkong
Responsible for Taiwan, Southeast Asia, and the Middle East Regional Marketing Hub
Company
Strive to become A leading global
brand in regenerative medicine
Shanghai
China Headquarter and R&D Center
Biopharmaceutical-grade
P1-level biosafety lab
Beijing
Biopharmaceutical-grade GMP
Recombinant exosome production and purification
Specialized intelligent manufacturing
Seattle
North America Headquarter
FDA-compliant recombinant exosome
manufacturing facility
Hongkong
Responsible for Taiwan, Southeast Asia, and the
Middle East
